MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
7.14
-0.32
-4.29%
After Hours: 7.20 +0.06 +0.84% 18:43 02/28 EST
OPEN
7.36
PREV CLOSE
7.46
HIGH
8.17
LOW
7.07
VOLUME
3.71M
TURNOVER
0
52 WEEK HIGH
8.63
52 WEEK LOW
1.630
MARKET CAP
708.56M
P/E (TTM)
-4.3662
1D
5D
1M
3M
1Y
5Y
Fate Therapeutics: Hold Rating Maintained Amid Anticipation of Pivotal Clinical Data
TipRanks · 1d ago
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Fate Therapeutics is a clinical-stage biopharmaceutical company. The company is engaged in the development of cell therapy programs for cancer and immune disorders. Fate Therapeutic has an average 12-month price target of $7.75. Four analysts have provided ratings for FateTherapeutics in the latest quarter.
Benzinga · 2d ago
Barclays Maintains Overweight on Fate Therapeutics, Raises Price Target to $10
Benzinga · 2d ago
Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y
NASDAQ · 2d ago
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Piper Sandler cut the price target for Unity Software Inc. (NYSE:U) on Monday. Oppenheimer increased the price targets for Domino's Pizza, Inc. And The Kroger Co. Morgan Stanley slashed the price of Unilever PLC's stock from $52 to $48. Barclays lowered PPG Industries' price target.
Benzinga · 2d ago
Wedbush Maintains Neutral on Fate Therapeutics, Raises Price Target to $7
Benzinga · 2d ago
Oppenheimer Reaffirms Their Hold Rating on Fate Therapeutics (FATE)
TipRanks · 2d ago
Oppenheimer Reiterates Perform on Fate Therapeuticsto Perform
Benzinga · 2d ago
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.

Webull offers Fate Therapeutics Inc stock information, including NASDAQ: FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.